Navigation Links
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
Date:6/3/2008

Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of clinical data for the MKC-1 Phase 2 study in patients with metastatic breast cancer. The data were presented by Bryan P. Schneider, M.D., Assistant Professor, Department of Medicine, Indiana University, during the Breast Cancer -- Metastatic session at the American Society of Clinical Oncology Annual Meeting being held this week in Chicago, Illinois.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3 patients who had responses and 5 patients with stable disease lasting more than four months.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. To date, MKC-1 has been evaluated in over 400 patients in multiple Phase 1 and 2 clinical trials.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medic
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
2. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
3. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
4. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
8. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
9. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
10. EntreMed Raises $20 Million to Support Clinical Development Program
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 26, 2012  Richard Wolf Medical Instruments Corporation celebrates ... minimally invasive solutions that spare patients the costs ... (Logo:  http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) ... allowing doctors to visualize and access elusive sites ...
... April 26, 2012 - The Consumer Healthcare Products ... for signing into law House Bill 363, legislation ... implementing a drug offender registry, stricter penalties for ... stop-sale technology.  HB 363 and its companion legislation ...
Cached Medicine Technology:Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... TeamHealth Medical Call Center (THMCC), a division of ... Center certificate of full accreditation from URAC, a ... standards for the health care industry. , ... services including nurse triage, customer/member services for health ...
... Tenn., July 7 King Pharmaceuticals, Inc. (NYSE: ... resubmission plan for the REMOXY(R) New Drug Application (NDA). ... Drug Administration (FDA) to conduct clinical trials in order to ... chronic pain. However, as part of the resubmission plan, ...
... Structural cardiovascular abnormalities present at birth are the leading ... million children in the United States have structural heart ... as small holes between chambers of the heart, to ... more chambers or valves. The July issue of ...
... ... testing whether specialized contact lenses can slow or halt the progression of near sightedness ... EyeVis Eye and Vision Research Institute, recently reported on initial results from the SMART ... ...
... Family Research Council President Tony Perkins responded ... President Obama,s executive order for federal funding of human ... and the NIH guidelines remove life-protecting limits on federal ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ...
... ... (MDS), a national leader in accounts receivable management, and collection services to the healthcare industry ... office in Vero Beach, Florida. , ... Vero Beach, FL (PRWEB) July 7, 2009 -- National healthcare receivables industry leader, ...
Cached Medicine News:Health News:TeamHealth Medical Call Center Awarded Third Consecutive URAC Health Call Center Accreditation 2Health News:King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan 2Health News:New strategies to improve treatment and ultimately prevent heart failure in children 2Health News:New strategies to improve treatment and ultimately prevent heart failure in children 3Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 2Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 3Health News:NIH Stem Cell Guidelines Ethically Irresponsible, Scientifically Unworthy, Useless to Patients, Says Family Research Council 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 3
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... VITROS Anti-HCV assay is the third diagnostic,hepatitis ... Drug,Administration capable of being run in a ... with Intellicheck. Now the laboratory staff,can run ... of more than 27 assays, and provide ...
... For use as a quality ... immunoglobulin M (IgM) antibodies to ... IgM), IgM antibodies to hepatitis ... B e antigen (HBeAg) and ...
Medicine Products: